SCN5A and Brugada syndrome: In patients with overlapping characteristics of LQTS (QT interval prolongation) and Brugada syndrome (ST segment elevation in leads V1 through V3), related to specific defects of the SCN5A gene, mexiletine does not induce ST segment elevation, unlike flecainide [34].